TABLE 1.

Demographics and comorbid conditions by treatment group

Covariate	Resulta for patients treated with:		P valueb
	Linezolid (n = 637)	Vancomycin (n = 19,470)
Age in yr, mean (SDc)	65.1 (14.0)	64.2 (13.6)	0.089
Race			0.032
White	371 (58.2)	11,250 (57.8)
African-American	72 (11.3)	2,955 (15.2)
Other	7 (1.1)	186 (0.9)
Unknown/missing	187 (29.4)	5,079 (26.1)
Gender			0.010
Male	611 (95.9)	18,992 (97.5)
Female	26 (4.1)	478 (2.5)
Charlson comorbidity index, median (IQRd)	2 (1-4)	2 (1-4)	0.135
Comorbid condition
Diabetes	251 (39.4)	7,966 (40.9)	0.445
Renal disease	191 (30.0)	5,214 (26.8)	0.073
Chronic respiratory disease	186 (29.2)	5,255 (27.0)	0.217
Coronary heart disease	185 (29.0)	5,464 (28.1)	0.589
Heart failure	127 (19.9)	3,774 (19.4)	0.728
Cancer	93 (14.6)	2,405 (12.4)	0.091
Amputation	48 (7.5)	1,013 (5.2)	0.010
Para- or quadriplegia	43 (6.8)	914 (4.7)	0.017
Hepatic disease	36 (5.7)	961 (4.9)	0.413
Cerebrovascular disease	32 (5.0)	1,322 (6.8)	0.080
HIV/AIDS	12 (1.9)	438 (2.3)	0.539
Transplant	9 (1.4)	193 (1.0)	0.294
Burns	4 (0.6)	83 (0.4)	0.358

^aData represent numbers of subjects, with percentages in parentheses, unless otherwise indicated.

^bDetermined by t test, χ² test, Fisher's exact test, or Wilcoxon rank-sum test as appropriate.

^cSD, standard deviation.

^dIQR, interquartile range.